Diagnosis and Prevention of Pneumococcal Community-Acquired Pneumonia

292 Pages·2015·3.16 MB·English

Diagnosis and Prevention of Pneumococcal
Community-Acquired Pneumonia
Susanne Marleen Huijts
Cover design: Liesbeth de Boer
Layout & print: Ridderprint, Ridderkerk, the Netherlands
ISBN: 978-94-6299-113-2
© 2015 S.M. Huijts, the Netherlands
All rights reserved. No part of this publication may be printed or utilised in any form without permission
of the copyright holder.
Printing of this thesis was financially supported by: Julius Clinical and Pfizer Nederland.
Diagnosis and Prevention of Pneumococcal
Community-Acquired Pneumonia
Diagnose en Preventie van thuis-opgelopen pneumonie
(met een samenvatting in het Nederlands)
Proefschrift
ter verkrijging van de graad van doctor aan de Universiteit Utrecht
op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan,
ingevolge het besluit van het college voor promoties
in het openbaar te verdedigen op dinsdag 23 juni 2015
des middags te 2.30 uur
door
Susanne Marleen Huijts
geboren op 24 november 1981
te Rotterdam
Promotor: Prof.dr. M.J.M. Bonten

Beoordelingscommissie: Prof.dr. A.I.M. Hoepelman
Prof.dr. P. Hermans
Prof.dr. J.W.J. Lammers
Prof.dr. M.J. Postma
Prof.dr.ir. H.A. Smit
Paranimfen: Lennie Derde
Anneke Hendrix
TABLE OF CONTENTS
Chapter 1 General introduction 9
PART ONE Diagnosis of Pneumococcal Community-Acquired pneumonia 23
Chapter 2 Validation of an Immunodiagnostic Assay for the Detection of 13 Streptococcus 25
pneumoniae Serotype-Specific Polysaccharides in Human Urine
Chapter 3 Diagnostic accuracy of a serotype specific antigen test in community-acquired 51
pneumonia
Chapter 4 Predicting Pneumococcal Community-Acquired Pneumonia in the 65
Emergency Department
Chapter 5 Guideline adherence for empirical treatment of pneumonia and patient outcome 79
PART TWO Prevention of Pneumococcal Community-Acquired Pneumonia 95
Chapter 6 Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal 97
vaccine efficacy among older adults
Chapter 7 Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults 107
Chapter 8 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands 137
Chapter 9 The effects of comorbidities on the efficacy of 13-valent pneumococcal conjugate 179
vaccine in elderly
Chapter 10 The impact of 13-valent pneumococcal conjugate vaccination on 201
virus-associated community-acquired pneumonia in elderly
Chapter 11 The impact of 13-valent pneumococcal conjugate vaccination on 215
pneumonia disease severity in elderly
Chapter 12 The scrutiny of Community-Acquired Pneumonia identification in population 233
based studies and implications for health care decisions: an example from a
pneumococcal vaccination trial
PART THREE Summary and discussion 251
Chapter 13 Summary and general discussion 253
Nederlandse samenvatting (Dutch summary) 271
Dankwoord (Acknowlegdements) 283
Curriculum vitae 289

1
Chapter
General introduction
Based on: New trends in the prevention and management of community-acquired pneumonia
D.F. Postma1, C.H. van Werkhoven1, S.M. Huijts1, M. Bolkenbaas1, J.J. Oosterheert2, M.J.M. Bonten1,3
1Julius Centre for Health Sciences, University Medical Centre Utrecht, the Netherlands; 2 Department of Internal Medicine
and Infectious Diseases, University Medical Centre Utrecht, the Netherlands; 3 Department of Medical Microbiology,
University Medical Centre Utrecht, the Netherlands
Neth J Med. 2012 Oct;70(8):337-48.